GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B5755 CYM 5541Summary: sphingosine-1-phosphate receptor 3 (S1P3) allosteric agonist -
B5776 CYM 50769Summary: neuropeptide W/B receptor 1 (NPBWR1, GPR7) antagonist -
B5778 SA 4503 dihydrochlorideSummary: σ1 receptor agonist -
B5787 ACT 335827Summary: Orexin receptor 1 antagonist,potent and selective -
B7065 SCH 442416Summary: adenosine A2A receptor antagonist -
B7118 J 113863Summary: chemokine receptor 1 (CCR1) antagonist -
B7228 CI 1020Summary: endothelin-A receptor (ETA) antagonist -
B7280 BMS CCR2 22Summary: CCR2 chemokine receptor antagonist -
B5333 SB 265610Summary: CXCR2 antagonist, potent -
B7508 NF 340Summary: P2Y11 antagonist
